Drug
AP01
Status:
Phase 2
Condition:
Other ILD
Intervention Type:
Inhaled Drug
Funder Type:
Industry
Drug Details
Avalyn has reformulated pirfenidone for inhalation, delivered via a hand-held nebulizer. This aerosolized formulation allows the antifibrotic drug to be delivered as a soft mist directly to the lung, in an effort to maximize pirfenidone’s effect on affected lung tissue while minimizing the undesired effects on systemic tissue that are associated with use of oral pirfenidone.
Study Purpose
This is a randomized, double-blind, placebo-controlled clinical study to evaluate the safety and efficacy of 2 doses of AP01 versus placebo on top of standard of care in participants with PPF over 52 weeks.